TORONTO, Sept. 29 /CNW/ - AIM Therapeutics Inc., announces that Dr.
Richard Timmer, President and CEO, will be presenting at BioContact Québec,
Fairmont Le Château Frontenac, Québec, on Wednesday, October 1, 2008 at
4:00 pm. He will also be presenting later this fall at BIO-Europe 2008,
Congress Center Rosengarten, Mannheim, Germany, on Tuesday, November 18, 2008.
Dr. Timmer will provide a brief corporate overview; discuss the company's
growth and how its novel neutropel technology inhibits inflammation.
About AIM Therapeutics Inc.:
AIM Therapeutics is a privately held biotechnology company focused on the
development of peptide-based therapeutic candidates for the treatment of
asthma, cardiovascular disease, diabetes, spinal cord injury, and other
inflammatory and immune disorders. The Company's therapeutic candidates are
based on research from leading scientists at the University of Western Ontario
and the University of Calgary. AIM Therapeutics is pursuing the pre-clinical
validation and development of its lead candidates through a virtual business
model being managed by BioQuest Innovations Inc.
For further information:
For further information: Dr. Richard Timmer, President and CEO, (416)
673-8433, firstname.lastname@example.org, www.aimtherapeutics.com; or Donna
Takacs, Investor and Corporate Relations, (416) 275-4180,